Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
October 30th 2024Dr. Alexander Drilon presents an update from the Phase 1/2 ALKOVE-1 study, investigating the efficacy and safety of NVL-655, a selective ALK inhibitor, in patients with ALK-positive solid tumors, highlighting durable responses in heavily pre-treated populations, including those with compound ALK resistance mutations and central nervous system involvement.
Read More
Dr. Drilon on Results of the Phase I/II LIBRETTO-001 Trial
September 10th 2019Alexander Drilon, MD, research director, Memorial Sloan Kettering Cancer Center, discusses the results of LIBRETTO-001, a phase I/II trial of RET inhibitor, selpercatinib in patients with RET fusion non-small cell lung cancers.
Read More
Dr. Drilon Discusses Efficacy Results With LOXO-292 in RET-Altered Solid Tumors
June 5th 2018Alexander Drilon, MD, medical oncologist, clinical director, Early Drug Development Service, Memorial Sloan Kettering Cancer Center, discusses findings from the phase I LIBRETTO-001 study exploring the highly selective RET inhibitor LOXO-292 in patients with RET-altered solid tumors.
Read More
Dr. Drilon on Entrectinib in Patients With ROS1-Positive NSCLC
October 17th 2017Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a study exploring entrectinib in patients with ROS1-positive, advanced or metastatic non-small cell lung cancer (NSCLC) during an interview at the IASLC 18th World Conference on Lung Cancer in Yokohama, Japan.
Read More